Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gel stop genital warts from coming back?

NCT ID NCT07698886

Disease control Sponsor: KTH Biopharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Sep 11, 2026 · Updated 9 times

Summary

This phase 2 trial tests whether applying a special gel (Geniwa gel) after laser removal can better treat recurrent genital warts and prevent them from returning. Adults who have had at least three laser treatments and still experience recurrences are eligible. Participants receive either the active gel or a placebo gel alongside laser treatment, and are monitored for wart clearance and recurrence over several months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Geniwa gel (alpha lactalbumin-oleic acid 5%)
What this could lead to
If effective, this combination could offer a way to clear recurrent genital warts and lower the chance of them coming back.
What could go wrong
This is a mid-stage trial with only 70 participants, so results may not apply to everyone. The gel may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years of age or older. 2. Able to read and understand the Patient Information Sheet and the Informed Consent form. 3. Acceptance in the participation of the essay and signature of the Informed Consent form. 4. Diagnosis of genital and anal warts with clear clinical manifestations. 5. Have undergone at least 2 laser treatments and have experienced recurrence in any location. 6. At least four or more lesions, or a lesion area of at least 0.5 cm2. Exclusion Criteria: 1. Concomitant sexually transmitted infections such as gonorrhea, syphilis, genital herpes, etc., that have not been cured. 2. Ulceration or suspected malignant transformation of the lesions. 3. Local infections. 4. Pregnant women. 5. Allergies to any component of alpha-lactalbumin-oleic acid gel.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genital warts are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anogenital human papillomavirus infection human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genital warts HPV (human papillomavirus)-associated

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Dermatology Hospital, Hanoi, Vietnam.

    RECRUITING

    Hanoi, None (International), 121000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.